Discovery of CBPD-409 as a Highly Potent, Selective, and Orally Efficacious CBP/p300 PROTAC Degrader for the Treatment of Advanced Prostate Cancer-Reference-Cited by-同舟云学术

Discovery of CBPD-409 as a Highly Potent, Selective, and Orally Efficacious CBP/p300 PROTAC Degrader for the Treatment of Advanced Prostate Cancer

Published:2024-03-26 Issue:7 Volume:67 Page:5351-5372
ISSN:0022-2623
Container-title:Journal of Medicinal Chemistry
language:en
Short-container-title:J. Med. Chem.

Author:

Chen Zhixiang¹,Wang Mi¹,Wu Dimin¹,Zhao Lijie¹,Metwally Hoda¹,Jiang Wei¹,Wang Yu¹,Bai Longchuan¹,McEachern Donna¹,Luo Jie²,Wang Meilin³,Li Qiuxia³,Matvekas Aleksas³,Wen Bo³,Sun Duxin³^ORCID,Chinnaiyan Arul M.²,Wang Shaomeng¹^ORCID

Affiliation:

1. The Rogel Cancer Center, Department of Internal Medicine, Department of Pharmacology, and Department of Medicinal Chemistry, University of Michigan, Ann Arbor, Michigan 48109, United States

2. Michigan Center for Translational Pathology, Department of Pathology, Rogel Cancer Center, University of Michigan Medical School, Ann Arbor, Michigan 48109, United States

3. Department of Pharmaceutical Sciences, College of Pharmacy, University of Michigan, Ann Arbor, Michigan 48109, United States

Funder

National Cancer Institute

Oncopia Therapeutics, Inc.

Proteovant Therapeutics, Inc

Publisher

American Chemical Society (ACS)

Link

https://pubs.acs.org/doi/pdf/10.1021/acs.jmedchem.3c01789

Reference53 articles.

1. Cancer statistics, 2023

2. Nuclear Localization of Androgen Receptor In Heterogeneous Samples Of Normal, Hyperplastic And Neoplastic Human Prostate